Physician profile
James Neiman
NPI 1902868128
$1,335.32
in general payments reported to CMS, 2019-2025
11 companies · $270 in 2025
The $270 reported for 2025 was more than what 93% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.23 · 2022: $519 · 2023: $286 · 2024: $177 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $380.62 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.10 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $167.68 | 2022-2025 | Simponi, Stelara, Remicade |
| Qol Medical, LLC | $123.51 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $85.89 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $76.88 | 2024-2025 | Ibsrela |
| Abbvie INC. | $62.08 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $36.55 | 2024 | Voquezna |
| Lilly USA, LLC | $33.74 | 2024 | Omvoh |
| Ironwood Pharmaceuticals, INC | $24.09 | 2023 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Neiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.